Kinfo
Elicio Therapeutics Inc. logo

Elicio Therapeutics Inc.

ELTXNASDAQHealthcare·US · USD
$1.40
-0.16 (-10.26%)
Prices as of November 5, 2026 · market closed

Price

Key statistics

Valuation
Market cap37.93M USD
Enterprise value30.62M USD
Trailing P/E5.75
Forward P/E-0.94
PEG ratio-0.16
Price / sales0.00
Price / book4.38
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-77.88%
Return on equity-774.56%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-37.74M USD
Net income-37.84M USD
Diluted EPS-$2.16
Rev. growth (YoY)0.00%
Balance sheet
Total cash23.48M USD
Total debt14.15M USD
Debt / equity178.25
Current ratio2.77
Book value / share$0.36
Cash flow (TTM)
Operating cash flow-37.69M USD
Levered free cash flow-22.32M USD
Shares & price
Shares outstanding21.90M
Float19.20M
Held by institutions20.57%
Beta2.00
50-day MA$2.00
200-day MA$6.72
52-week high$16.00
52-week low$1.40
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-13-0.54-0.43+20.37%2026-06-24-0.02-0.02+0.00%2026-06-100.430.43+0.00%2026-05-11-0.46-0.65−41.30%2026-03-12-0.44-0.49−11.36%
About Elicio Therapeutics Inc.

Elicio Therapeutics Inc. is a clinical-stage biotechnology company focused on developing lymph node-targeted immunotherapies for cancer. The company’s current pipeline centers on its Amphiphile (AMP) platform, which is designed to deliver vaccines, immunomodulators, and adjuvants to the lymph nodes to support a stronger immune response. Its programs include investigational therapies for KRAS-driven cancers, BRAF-driven cancers, and other mutation-defined tumor types, alongside broader efforts in cancer immunotherapy and selected infectious disease applications. Elicio Therapeutics Inc. works at the intersection of oncology and immune system engineering, using platform-based drug design to create both personalized and off-the-shelf candidates for clinically important targets. Headquartered in Boston, Massachusetts, Elicio Therapeutics Inc. is positioned as a specialized player in the biotechnology market with a focus on hard-to-treat cancers and precision immunotherapy approaches.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Robert T. Connelly
Employees
32
Headquarters
Boston, MA, United States
Website
elicio.com

Frequently asked questions about Elicio Therapeutics Inc.